Checkpoint Blockade, Immune for Skin Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Skin Cancer+2 MoreCheckpoint Blockade, Immune - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether adding 30 minutes of exercise before each immunotherapy treatment can improve outcomes.

Eligible Conditions
  • Skin Cancer
  • Cutaneous Neuroendocrine Carcinoma
  • Skin Squamous Cell Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Cemiplimab
1
RP1, intra-tumoral injection, oncolytic virus
1
ITI-3000

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: Up to 12 months

Up to 12 Months
Impact of Exercise on Tumor Immunological Biomarkers - Adjuvant Setting
Up to 12 months
Participants Completing Exercise
Participants Consenting to Trial
Up to 4 Months
Impact of Exercise on Tumor Immunological Biomarkers - Neoadjuvant Setting

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Cemiplimab
1
RP1, intra-tumoral injection, oncolytic virus
1
ITI-3000

Trial Design

4 Treatment Groups

Adjuvant Arm without Exercise
1 of 4
NeoAdjuvant Arm without Exercise
1 of 4
NeoAdjuvant Arm with Exercise
1 of 4
Adjuvant Arm with Exercise
1 of 4

Active Control

Experimental Treatment

32 Total Participants · 4 Treatment Groups

Primary Treatment: Checkpoint Blockade, Immune · No Placebo Group · Phase < 1

NeoAdjuvant Arm with ExerciseExperimental Group · 3 Interventions: Walking, Checkpoint Blockade, Immune, Excerise · Intervention Types: Other, Drug, Other
Adjuvant Arm with ExerciseExperimental Group · 3 Interventions: Walking, Checkpoint Blockade, Immune, Excerise · Intervention Types: Other, Drug, Other
Adjuvant Arm without Exercise
Drug
ActiveComparator Group · 1 Intervention: Checkpoint Blockade, Immune · Intervention Types: Drug
NeoAdjuvant Arm without Exercise
Drug
ActiveComparator Group · 1 Intervention: Checkpoint Blockade, Immune · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 months

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
504 Previous Clinical Trials
125,981 Total Patients Enrolled
Peter Kanetsky, PhD, MPHPrincipal InvestigatorMoffitt Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to walk unaided for 6 minutes or more.
Patients with Merkel cell carcinoma are at high risk for metastasis.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top